You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation

  • Technology appraisal guidance
  • Reference number: TA311
  • Published:  23 April 2014
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Multiple myeloma - bortezomib (induction therapy): FAD document

Multiple myeloma - bortezomib (induction therapy): FAD document Multiple myeloma - bortezomib (induction therapy): FAD document
21 March 2014
(428.13 Kb 4 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 18 March 2014

Back to top